NCT04408456View on ClinicalTrials.gov

Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19

PHASE3CompletedINTERVENTIONAL
Enrollment

325

Participants

Timeline

Start Date

March 1, 2020

Primary Completion Date

July 31, 2020

Study Completion Date

July 31, 2020

Conditions
CoVID-19
Interventions
DRUG

HCQ

Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total cumulative dose of 2000 mg)

OTHER

Standard therapy

Home quarantine for 2 weeks plus social distancing plus personal hygiene

Trial Locations (2)

160012

Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh

Post Graduate Institute of Medical Education and Research, Chandigarh

All Listed Sponsors
lead

Post Graduate Institute of Medical Education and Research, Chandigarh

OTHER

NCT04408456 - Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19 | Biotech Hunter | Biotech Hunter